|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, August 15, 2012 ) New York, NY -- A Tuesday update by Synergy Pharmaceuticals (SGYP) set the stage for the company to potentially realize significant end-of-year milestones, as noted by VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors.
Full report is available by visiting: http://vfcsstockhouse.com/blog/article/-synergy-pharmaceuticals-tuesday-trial-update-confirms-end-of-year-milestone-results
Shares of Synergy Pharmaceuticals were already sliding to below the four dollar mark when a recently-announced merger with Callisto Pharmaceuticals (CLSP) looked to have paved the way for a larger and more committed investor base to take up positions in the company. While that slide continued at the open of the current trading week, a Tuesday morning trial update by Synergy reinforced the potential of the company's flagship product, Plecanatide, in preparing to enter a multi billion dollar market.
According to Tuesday's press release, linked above, the company has completed enrollment of the Phase IIb/III clinical trial measuring the effectiveness of Plecanatide in treating chronic idiopathic constipation (CIC). This milestone event was already highly anticipated to conclude in the near future, but it reinforces previous expectations that results will be released by year-end 2012.
Although you can't bank on sure things in this highly-volatile and unpredictable sector, it is widely expected that the results from this trial will be positive. Ironwood Pharmaceuticals (IRWD) has already submitted with the FDA for the approval of Linaclotide - a treatment designed for the same indications and shares origins and the same mechanism of action with Plecanatide - and a decision is expected to take place next month. A trial delay announced this spring allowed Plecanatide to play a bit of 'catch up' in the path towards commercialization, but Tuesday's Synergy announcement keeps its developmental timeline in tact.
In the end, however, Synergy may hold a distinct advantage over Ironwood and could still make SGYP the more compelling play. During Ironwood's Linaclotide trials, the treatment was successful in alleviating constipation when compared to a placebo, but the kicker is that side effects included cases of extreme diarrhea. Some cases were extreme enough to force 6% of the patients to abandon the trial altogether. No such side effects were noted during Plecanatide trials, according to publicly-released information.
For full list of this week's hot stocks to watch visit: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-13-august-amrn-mric-sppi-ssh-imsc-bsx-alth-si-cpst-ttnp-cvm
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
